The global Whooping Cough Vaccination market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Whooping cough vaccination is a vaccine that protects against whooping cough (pertussis). There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective.

From a downstream perspective, 12 Months Below accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Whooping Cough Vaccination leading manufacturers including Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products, Minhai Biotechnology, etc., dominate supply; the top five capture approximately % of global revenue, with Sanofi Pasteur leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Whooping Cough Vaccination market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Whooping Cough Vaccination Market Report

Report Metric	Details
Report Name	Whooping Cough Vaccination Market
Segment by Type	Acellular Vaccines Whole-Cell Vaccines
Segment by Application	12 Months Below 12 Months Above
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products, Minhai Biotechnology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Whooping Cough Vaccination study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Whooping Cough Vaccination Market report?

Ans: The main players in the Whooping Cough Vaccination Market are Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, KM Biologics, Wuhan Institute of Biological Products, Walvax Biotechnology, Chengdu Institute of Biological Products, Minhai Biotechnology

What are the Application segmentation covered in the Whooping Cough Vaccination Market report?

Ans: The Applications covered in the Whooping Cough Vaccination Market report are 12 Months Below, 12 Months Above

What are the Type segmentation covered in the Whooping Cough Vaccination Market report?

Ans: The Types covered in the Whooping Cough Vaccination Market report are Acellular Vaccines, Whole-Cell Vaccines

1 Study Coverage

1.1 Introduction to Whooping Cough Vaccination: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Whooping Cough Vaccination Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Acellular Vaccines

1.2.3 Whole-Cell Vaccines

1.3 Market Segmentation by Application

1.3.1 Global Whooping Cough Vaccination Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 12 Months Below

1.3.3 12 Months Above

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Whooping Cough Vaccination Revenue Estimates and Forecasts 2020-2031

2.2 Global Whooping Cough Vaccination Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Whooping Cough Vaccination Sales Estimates and Forecasts 2020-2031

2.4 Global Whooping Cough Vaccination Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Whooping Cough Vaccination Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Whooping Cough Vaccination Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Acellular Vaccines Market Size by Manufacturers

3.5.2 Whole-Cell Vaccines Market Size by Manufacturers

3.6 Global Whooping Cough Vaccination Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Whooping Cough Vaccination Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Whooping Cough Vaccination Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Whooping Cough Vaccination Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Whooping Cough Vaccination Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Whooping Cough Vaccination Sales and Revenue by Type (2020-2031)

6.4 North America Whooping Cough Vaccination Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Whooping Cough Vaccination Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Whooping Cough Vaccination Sales and Revenue by Type (2020-2031)

7.4 Europe Whooping Cough Vaccination Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Whooping Cough Vaccination Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Whooping Cough Vaccination Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Whooping Cough Vaccination Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Whooping Cough Vaccination Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Whooping Cough Vaccination Sales and Revenue by Type (2020-2031)

9.4 Central and South America Whooping Cough Vaccination Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Whooping Cough Vaccination Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Whooping Cough Vaccination Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Whooping Cough Vaccination Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Whooping Cough Vaccination Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Sanofi Pasteur

11.1.1 Sanofi Pasteur Corporation Information

11.1.2 Sanofi Pasteur Business Overview

11.1.3 Sanofi Pasteur Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.1.4 Sanofi Pasteur Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Sanofi Pasteur Whooping Cough Vaccination Sales by Product in 2024

11.1.6 Sanofi Pasteur Whooping Cough Vaccination Sales by Application in 2024

11.1.7 Sanofi Pasteur Whooping Cough Vaccination Sales by Geographic Area in 2024

11.1.8 Sanofi Pasteur Whooping Cough Vaccination SWOT Analysis

11.1.9 Sanofi Pasteur Recent Developments

11.2 GSK

11.2.1 GSK Corporation Information

11.2.2 GSK Business Overview

11.2.3 GSK Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.2.4 GSK Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 GSK Whooping Cough Vaccination Sales by Product in 2024

11.2.6 GSK Whooping Cough Vaccination Sales by Application in 2024

11.2.7 GSK Whooping Cough Vaccination Sales by Geographic Area in 2024

11.2.8 GSK Whooping Cough Vaccination SWOT Analysis

11.2.9 GSK Recent Developments

11.3 Mitsubishi Tanabe Pharma

11.3.1 Mitsubishi Tanabe Pharma Corporation Information

11.3.2 Mitsubishi Tanabe Pharma Business Overview

11.3.3 Mitsubishi Tanabe Pharma Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.3.4 Mitsubishi Tanabe Pharma Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Mitsubishi Tanabe Pharma Whooping Cough Vaccination Sales by Product in 2024

11.3.6 Mitsubishi Tanabe Pharma Whooping Cough Vaccination Sales by Application in 2024

11.3.7 Mitsubishi Tanabe Pharma Whooping Cough Vaccination Sales by Geographic Area in 2024

11.3.8 Mitsubishi Tanabe Pharma Whooping Cough Vaccination SWOT Analysis

11.3.9 Mitsubishi Tanabe Pharma Recent Developments

11.4 KM Biologics

11.4.1 KM Biologics Corporation Information

11.4.2 KM Biologics Business Overview

11.4.3 KM Biologics Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.4.4 KM Biologics Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 KM Biologics Whooping Cough Vaccination Sales by Product in 2024

11.4.6 KM Biologics Whooping Cough Vaccination Sales by Application in 2024

11.4.7 KM Biologics Whooping Cough Vaccination Sales by Geographic Area in 2024

11.4.8 KM Biologics Whooping Cough Vaccination SWOT Analysis

11.4.9 KM Biologics Recent Developments

11.5 Wuhan Institute of Biological Products

11.5.1 Wuhan Institute of Biological Products Corporation Information

11.5.2 Wuhan Institute of Biological Products Business Overview

11.5.3 Wuhan Institute of Biological Products Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.5.4 Wuhan Institute of Biological Products Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Wuhan Institute of Biological Products Whooping Cough Vaccination Sales by Product in 2024

11.5.6 Wuhan Institute of Biological Products Whooping Cough Vaccination Sales by Application in 2024

11.5.7 Wuhan Institute of Biological Products Whooping Cough Vaccination Sales by Geographic Area in 2024

11.5.8 Wuhan Institute of Biological Products Whooping Cough Vaccination SWOT Analysis

11.5.9 Wuhan Institute of Biological Products Recent Developments

11.6 Walvax Biotechnology

11.6.1 Walvax Biotechnology Corporation Information

11.6.2 Walvax Biotechnology Business Overview

11.6.3 Walvax Biotechnology Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.6.4 Walvax Biotechnology Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Walvax Biotechnology Recent Developments

11.7 Chengdu Institute of Biological Products

11.7.1 Chengdu Institute of Biological Products Corporation Information

11.7.2 Chengdu Institute of Biological Products Business Overview

11.7.3 Chengdu Institute of Biological Products Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.7.4 Chengdu Institute of Biological Products Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Chengdu Institute of Biological Products Recent Developments

11.8 Minhai Biotechnology

11.8.1 Minhai Biotechnology Corporation Information

11.8.2 Minhai Biotechnology Business Overview

11.8.3 Minhai Biotechnology Whooping Cough Vaccination Product Models, Descriptions and Specifications

11.8.4 Minhai Biotechnology Whooping Cough Vaccination Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Minhai Biotechnology Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Whooping Cough Vaccination Industry Chain

12.2 Whooping Cough Vaccination Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Whooping Cough Vaccination Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Whooping Cough Vaccination Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Whooping Cough Vaccination Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Whooping Cough Vaccination Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Sanofi Pasteur

GSK

Mitsubishi Tanabe Pharma

KM Biologics

Wuhan Institute of Biological Products

Walvax Biotechnology

Chengdu Institute of Biological Products

Minhai Biotechnology

List of Tables

Table 1. Global Whooping Cough Vaccination Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Whooping Cough Vaccination Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Whooping Cough Vaccination Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Whooping Cough Vaccination Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Whooping Cough Vaccination Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Whooping Cough Vaccination Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)

Table 7. Global Whooping Cough Vaccination Sales by Region (2020-2025) & (K Dose)

Table 8. Global Whooping Cough Vaccination Sales by Region (2026-2031) & (K Dose)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Whooping Cough Vaccination Sales by Manufacturers (2020-2025) & (K Dose)

Table 11. Global Whooping Cough Vaccination Sales Share by Manufacturers (2020-2025)

Table 12. Global Whooping Cough Vaccination Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Whooping Cough Vaccination Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Whooping Cough Vaccination by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Whooping Cough Vaccination as of 2024)

Table 16. Global Whooping Cough Vaccination Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Whooping Cough Vaccination Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)

Table 18. Key Manufacturers Whooping Cough Vaccination Manufacturing Base and Headquarters

Table 19. Global Whooping Cough Vaccination Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Whooping Cough Vaccination Sales by Type (2020-2025) & (K Dose)

Table 23. Global Whooping Cough Vaccination Sales by Type (2026-2031) & (K Dose)

Table 24. Global Whooping Cough Vaccination Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Whooping Cough Vaccination Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Whooping Cough Vaccination ASP by Type (2020-2031) & (US$/Dose)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Whooping Cough Vaccination Sales by Application (2020-2025) & (K Dose)

Table 29. Global Whooping Cough Vaccination Sales by Application (2026-2031) & (K Dose)

Table 30. Whooping Cough Vaccination High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Whooping Cough Vaccination Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Whooping Cough Vaccination Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Whooping Cough Vaccination ASP by Application (2020-2031) & (US$/Dose)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Whooping Cough Vaccination Growth Accelerators and Market Barriers

Table 37. North America Whooping Cough Vaccination Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Whooping Cough Vaccination Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Whooping Cough Vaccination Growth Accelerators and Market Barriers

Table 40. Europe Whooping Cough Vaccination Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Whooping Cough Vaccination Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Whooping Cough Vaccination Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Whooping Cough Vaccination Sales (K Dose) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Whooping Cough Vaccination Growth Accelerators and Market Barriers

Table 45. Southeast Asia Whooping Cough Vaccination Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Whooping Cough Vaccination Investment Opportunities and Key Challenges

Table 47. Central and South America Whooping Cough Vaccination Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Whooping Cough Vaccination Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Whooping Cough Vaccination Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Sanofi Pasteur Corporation Information

Table 51. Sanofi Pasteur Description and Major Businesses

Table 52. Sanofi Pasteur Product Models, Descriptions and Specifications

Table 53. Sanofi Pasteur Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 54. Sanofi Pasteur Sales Value Proportion by Product in 2024

Table 55. Sanofi Pasteur Sales Value Proportion by Application in 2024

Table 56. Sanofi Pasteur Sales Value Proportion by Geographic Area in 2024

Table 57. Sanofi Pasteur Whooping Cough Vaccination SWOT Analysis

Table 58. Sanofi Pasteur Recent Developments

Table 59. GSK Corporation Information

Table 60. GSK Description and Major Businesses

Table 61. GSK Product Models, Descriptions and Specifications

Table 62. GSK Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 63. GSK Sales Value Proportion by Product in 2024

Table 64. GSK Sales Value Proportion by Application in 2024

Table 65. GSK Sales Value Proportion by Geographic Area in 2024

Table 66. GSK Whooping Cough Vaccination SWOT Analysis

Table 67. GSK Recent Developments

Table 68. Mitsubishi Tanabe Pharma Corporation Information

Table 69. Mitsubishi Tanabe Pharma Description and Major Businesses

Table 70. Mitsubishi Tanabe Pharma Product Models, Descriptions and Specifications

Table 71. Mitsubishi Tanabe Pharma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 72. Mitsubishi Tanabe Pharma Sales Value Proportion by Product in 2024

Table 73. Mitsubishi Tanabe Pharma Sales Value Proportion by Application in 2024

Table 74. Mitsubishi Tanabe Pharma Sales Value Proportion by Geographic Area in 2024

Table 75. Mitsubishi Tanabe Pharma Whooping Cough Vaccination SWOT Analysis

Table 76. Mitsubishi Tanabe Pharma Recent Developments

Table 77. KM Biologics Corporation Information

Table 78. KM Biologics Description and Major Businesses

Table 79. KM Biologics Product Models, Descriptions and Specifications

Table 80. KM Biologics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 81. KM Biologics Sales Value Proportion by Product in 2024

Table 82. KM Biologics Sales Value Proportion by Application in 2024

Table 83. KM Biologics Sales Value Proportion by Geographic Area in 2024

Table 84. KM Biologics Whooping Cough Vaccination SWOT Analysis

Table 85. KM Biologics Recent Developments

Table 86. Wuhan Institute of Biological Products Corporation Information

Table 87. Wuhan Institute of Biological Products Description and Major Businesses

Table 88. Wuhan Institute of Biological Products Product Models, Descriptions and Specifications

Table 89. Wuhan Institute of Biological Products Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 90. Wuhan Institute of Biological Products Sales Value Proportion by Product in 2024

Table 91. Wuhan Institute of Biological Products Sales Value Proportion by Application in 2024

Table 92. Wuhan Institute of Biological Products Sales Value Proportion by Geographic Area in 2024

Table 93. Wuhan Institute of Biological Products Whooping Cough Vaccination SWOT Analysis

Table 94. Wuhan Institute of Biological Products Recent Developments

Table 95. Walvax Biotechnology Corporation Information

Table 96. Walvax Biotechnology Description and Major Businesses

Table 97. Walvax Biotechnology Product Models, Descriptions and Specifications

Table 98. Walvax Biotechnology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 99. Walvax Biotechnology Recent Developments

Table 100. Chengdu Institute of Biological Products Corporation Information

Table 101. Chengdu Institute of Biological Products Description and Major Businesses

Table 102. Chengdu Institute of Biological Products Product Models, Descriptions and Specifications

Table 103. Chengdu Institute of Biological Products Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 104. Chengdu Institute of Biological Products Recent Developments

Table 105. Minhai Biotechnology Corporation Information

Table 106. Minhai Biotechnology Description and Major Businesses

Table 107. Minhai Biotechnology Product Models, Descriptions and Specifications

Table 108. Minhai Biotechnology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 109. Minhai Biotechnology Recent Developments

Table 110. Key Raw Materials Distribution

Table 111. Raw Materials Key Suppliers

Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 113. Milestones in Production Technology Evolution

Table 114. Distributors List

Table 115. Market Trends and Market Evolution

Table 116. Market Drivers and Opportunities

Table 117. Market Challenges, Risks, and Restraints

Table 118. Research Programs/Design for This Report

Table 119. Key Data Information from Secondary Sources

Table 120. Key Data Information from Primary Sources

List of Figures

Figure 1. Whooping Cough Vaccination Product Picture

Figure 2. Global Whooping Cough Vaccination Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Acellular Vaccines Product Picture

Figure 4. Whole-Cell Vaccines Product Picture

Figure 5. Global Whooping Cough Vaccination Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. 12 Months Below

Figure 7. 12 Months Above

Figure 8. Whooping Cough Vaccination Report Years Considered

Figure 9. Global Whooping Cough Vaccination Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 10. Global Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 11. Global Whooping Cough Vaccination Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 12. Global Whooping Cough Vaccination Revenue Market Share by Region (2020-2031)

Figure 13. Global Whooping Cough Vaccination Sales (2020-2031) & (K Dose)

Figure 14. Global Whooping Cough Vaccination Sales (CAGR) by Region (2020-2031) (K Dose)

Figure 15. Global Whooping Cough Vaccination Sales Market Share by Region (2020-2031)

Figure 16. Top 5 and Top 10 Manufacturers Whooping Cough Vaccination Sales Volume Market Share in 2024

Figure 17. Global Whooping Cough Vaccination Revenue Market Share Ranking (2024)

Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 19. Acellular Vaccines Revenue Market Share by Manufacturer in 2024

Figure 20. Whole-Cell Vaccines Revenue Market Share by Manufacturer in 2024

Figure 21. Global Whooping Cough Vaccination Sales Market Share by Type (2020-2031)

Figure 22. Global Whooping Cough Vaccination Revenue Market Share by Type (2020-2031)

Figure 23. Global Whooping Cough Vaccination Sales Market Share by Application (2020-2031)

Figure 24. Global Whooping Cough Vaccination Revenue Market Share by Application (2020-2031)

Figure 25. North America Whooping Cough Vaccination Sales YoY (2020-2031) & (K Dose)

Figure 26. North America Whooping Cough Vaccination Revenue YoY (2020-2031) & (US$ Million)

Figure 27. North America Top 5 Manufacturers Whooping Cough Vaccination Sales Revenue (US$ Million) in 2024

Figure 28. North America Whooping Cough Vaccination Sales Volume (K Dose) by Type (2020- 2031)

Figure 29. North America Whooping Cough Vaccination Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 30. North America Whooping Cough Vaccination Sales Volume (K Dose) by Application (2020-2031)

Figure 31. North America Whooping Cough Vaccination Sales Revenue (US$ Million) by Application (2020-2031)

Figure 32. US Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 33. Canada Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 34. Mexico Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 35. Europe Whooping Cough Vaccination Sales YoY (2020-2031) & (K Dose)

Figure 36. Europe Whooping Cough Vaccination Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Europe Top 5 Manufacturers Whooping Cough Vaccination Sales Revenue (US$ Million) in 2024

Figure 38. Europe Whooping Cough Vaccination Sales Volume (K Dose) by Type (2020-2031)

Figure 39. Europe Whooping Cough Vaccination Sales Revenue (US$ Million) by Type (2020-2031)

Figure 40. Europe Whooping Cough Vaccination Sales Volume (K Dose) by Application (2020-2031)

Figure 41. Europe Whooping Cough Vaccination Sales Revenue (US$ Million) by Application (2020-2031)

Figure 42. Germany Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 43. France Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 44. U.K. Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 45. Italy Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 46. Russia Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 47. Asia-Pacific Whooping Cough Vaccination Sales YoY (2020-2031) & (K Dose)

Figure 48. Asia-Pacific Whooping Cough Vaccination Revenue YoY (2020-2031) & (US$ Million)

Figure 49. Asia-Pacific Top 8 Manufacturers Whooping Cough Vaccination Sales Revenue (US$ Million) in 2024

Figure 50. Asia-Pacific Whooping Cough Vaccination Sales Volume (K Dose) by Type (2020- 2031)

Figure 51. Asia-Pacific Whooping Cough Vaccination Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 52. Asia-Pacific Whooping Cough Vaccination Sales Volume (K Dose) by Application (2020-2031)

Figure 53. Asia-Pacific Whooping Cough Vaccination Sales Revenue (US$ Million) by Application (2020-2031)

Figure 54. Indonesia Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 55. Japan Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 56. South Korea Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 57. China Taiwan Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 58. India Whooping Cough Vaccination Revenue (2020-2031) & (US$ Million)

Figure 59. Central and South America Whooping Cough Vaccination Sales YoY (2020-2031) & (K Dose)

Figure 60. Central and South America Whooping Cough Vaccination Revenue YoY (2020-2031) & (US$ Million)

Figure 61. Central and South America Top 5 Manufacturers Whooping Cough Vaccination Sales Revenue (US$ Million) in 2024

Figure 62. Central and South America Whooping Cough Vaccination Sales Volume (K Dose) by Type (2021-2031)

Figure 63. Central and South America Whooping Cough Vaccination Sales Revenue (US$ Million) by Type (2020-2031)

Figure 64. Central and South America Whooping Cough Vaccination Sales Volume (K Dose) by Application (2020-2031)

Figure 65. Central and South America Whooping Cough Vaccination Sales Revenue (US$ Million) by Application (2020-2031)

Figure 66. Brazil Whooping Cough Vaccination Revenue (2020-2025) & (US$ Million)

Figure 67. Argentina Whooping Cough Vaccination Revenue (2020-2025) & (US$ Million)

Figure 68. Middle East, and Africa Whooping Cough Vaccination Sales YoY (2020-2031) & (K Dose)

Figure 69. Middle East and Africa Whooping Cough Vaccination Revenue YoY (2020-2031) & (US$ Million)

Figure 70. Middle East and Africa Top 5 Manufacturers Whooping Cough Vaccination Sales Revenue (US$ Million) in 2024

Figure 71. Middle East and Africa Whooping Cough Vaccination Sales Volume (K Dose) by Type (2021-2031)

Figure 72. South America Whooping Cough Vaccination Sales Revenue (US$ Million) by Type (2020-2031)

Figure 73. Middle East and Africa Whooping Cough Vaccination Sales Volume (K Dose) by Application (2020-2031)

Figure 74. Middle East and Africa Whooping Cough Vaccination Sales Revenue (US$ Million) by Application (2020-2031)

Figure 75. GCC Countries Whooping Cough Vaccination Revenue (2020-2025) & (US$ Million)

Figure 76. Turkey Whooping Cough Vaccination Revenue (2020-2025) & (US$ Million)

Figure 77. Egypt Whooping Cough Vaccination Revenue (2020-2025) & (US$ Million)

Figure 78. South Africa Whooping Cough Vaccination Revenue (2020-2025) & (US$ Million)

Figure 79. Whooping Cough Vaccination Industry Chain Mapping

Figure 80. Regional Whooping Cough Vaccination Manufacturing Base Distribution (%)

Figure 81. Global Whooping Cough Vaccination Production Market Share by Region (2020-2031)

Figure 82. Whooping Cough Vaccination Production Process

Figure 83. Regional Whooping Cough Vaccination Production Cost Structure

Figure 84. Channels of Distribution (Direct Vs Distribution)

Figure 85. Bottom-up and Top-down Approaches for This Report

Figure 86. Data Triangulation

Figure 87. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions